UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 715

Sortiert nach

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1689-1699

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Clinical cancer research, 2019-09, Vol.25 (18), p.5485-5492

2019

Link zum Volltext

Verfügbarkeit prüfen

The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning

Biomolecules (Basel, Switzerland), 2020-07, Vol.10 (8), p.1123

2020

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.841-849

2018

Link zum Volltext

Verfügbarkeit prüfen

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Cancer science, 2018-11, Vol.109 (11), p.3583-3590

2018

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Japanese journal of clinical oncology, 2019-01, Vol.49 (1), p.29-36

2019

Link zum Volltext

Verfügbarkeit prüfen

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Link zum Volltext

Verfügbarkeit prüfen

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

European journal of cancer (1990), 2019-05, Vol.113, p.78-86

2019

Link zum Volltext

Verfügbarkeit prüfen

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group

Japanese journal of clinical oncology, 2020-05, Vol.50 (5), p.502-511

2020

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient

Japanese journal of clinical oncology, 2019-08, Vol.49 (8), p.793-794

2019

Link zum Volltext

Verfügbarkeit prüfen

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

Lung cancer (Amsterdam, Netherlands), 2015-05, Vol.88 (2), p.154-159

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Cancer science, 2022-12, Vol.113 (12), p.4300-4310

2022

Link zum Volltext

Verfügbarkeit prüfen

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

The lancet oncology, 2013-06, Vol.14 (7), p.590-598

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Scientific reports, 2021-09, Vol.11 (1), p.18762-18762, Article 18762

2021

Link zum Volltext

Verfügbarkeit prüfen

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2018-10, Vol.124, p.179-188

2018

Link zum Volltext

Verfügbarkeit prüfen

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

The lancet respiratory medicine, 2017-01, Vol.5 (1), p.42-50

2017

Link zum Volltext

Verfügbarkeit prüfen

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature communications, 2023-02, Vol.14 (1), p.1070-1070, Article 1070

2023

Link zum Volltext

Verfügbarkeit prüfen

CD20+ tumor‐infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma

Cancer science, 2020-06, Vol.111 (6), p.1921-1932

2020

Link zum Volltext

Verfügbarkeit prüfen

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Cancer Immunology, Immunotherapy, 2020-01, Vol.69 (1), p.15-22

2020

Link zum Volltext

Verfügbarkeit prüfen

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression

Clinical cancer research, 2021-03, Vol.27 (5), p.1410-1420

2021

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic Outcomes and Safety of Cryobiopsy Added to Conventional Sampling Methods

Chest, 2021-11, Vol.160 (5), p.1890-1901

2021

Link zum Volltext

Verfügbarkeit prüfen

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer

PloS one, 2014-07, Vol.9 (7), p.e102436

2014

Link zum Volltext

Verfügbarkeit prüfen

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Lung cancer (Amsterdam, Netherlands), 2018-03, Vol.117, p.14-19

2018

Link zum Volltext

Verfügbarkeit prüfen

Adenovirus pneumonia mimicking osimertinib‐induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report

Thoracic cancer, 2024-03, Vol.15 (9), p.749-751

2024

Link zum Volltext

Verfügbarkeit prüfen

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

The lancet oncology, 2012-07, Vol.13 (7), p.671-678

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 715

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(641)
Mit Volltextzugriff
(692)

Publikationsform

Sprache

Englisch
(671)
Japanisch
(172)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(418)
Life Sciences & Biomedicine
(410)
Oncology
(375)
Humans
(351)
Female
(243)
Male
(240)
Aged
(227)
Middle Aged
(217)
Lung Neoplasms - Drug Therapy
(210)
Adult
(172)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(157)
Lung Cancer
(138)
Lung Neoplasms - Pathology
(118)
Chemotherapy
(111)
Cancer Research
(103)
Respiratory System
(100)
Aged, 80 And Over
(97)
Biological And Medical Sciences
(87)
Retrospective Studies
(85)
Medical Sciences
(84)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group

Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

CD20+ tumor‐infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression

Diagnostic Outcomes and Safety of Cryobiopsy Added to Conventional Sampling Methods

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Adenovirus pneumonia mimicking osimertinib‐induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

Suchergebnisse filtern